Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.32    
    

AMENDMENT
NO.1

TO THE DISTRIBUTION & INVENTORY MANAGEMENT

SERVICES AGREEMENT 

        THIS
AMENDMENT NO. 1, dated as of December 10th, 2004 (the "Amendment"), by and between Cardinal Health*, an Ohio corporation with its principal place of business
located at 7000 Cardinal Place, Dublin, OH 43017 ("Cardinal Health"), and Prometheus Laboratories Inc. ("Prometheus"), amends the Distribution & Inventory Management Services Agreement,
dated as of June 1st, by and between Cardinal Health and Prometheus, as follows (unless otherwise defined herein, all capitalized terms shall have the same meaning ascribed to
them in the Agreement): 

	1.
	Addition of a New Product NDC# to Distribution and Inventory Management Services Agreement  

        The Distribution & Inventory Management Services Agreement by and between Cardinal Health and Prometheus shall be amended to expand the Exhibit A
Products Section to include one (1) new NDC Product #'s as follows: 

	Current NDC#
	 	Product Description

	00186-0702-10	 	Entocort® EC 3mg Capsules

        The
new NDC # will be added to the Distribution & Inventory management Services Agreement Exhibit A Products section and have an effective date of
January 1st, 2005. 

        All
other Terms and Conditions of the Distribution & Inventory Management Services Agreements will remain in effect. 

        IN
WITNESS WHEREOF, the parties hereto have caused the Amendment to be duly executed as of the date first set forth above. 

	Prometheus Laboratories Inc.	 	Cardinal Health*
	

By:	
 	

/s/  MICHAEL SWANSON      
 Name: Michael Swanson

Title: VP, Finance and Chief Financial Officer

Prometheus Laboratories, Inc.	
 	

By:	
 	

/s/  JIM SCOTT      
 Name: Jim Scott

Title: SVP, Purchasing

Cardinal Health Inc.

	*
	The
term "Cardinal Health" shall include the following affiliated operating companies: Cardinal Health 110, Inc., formerly known as Whitmire Distribution Corporation, a Delaware
corporation (Folsom, California); Cardinal Health 106, Inc., formerly known as James W. Daly, Inc., a Massachusetts corporation (Peabody, Massachusetts); Cardinal Health
103, Inc., formerly known as Cardinal Southeast, Inc., a Mississippi corporation (Richland, Mississippi); Cardinal Health 100, Inc., formerly known as Bindley Western
Industries, Inc., an Indiana corporation (Indianapolis, Indiana); Cardinal Health 104, LP f/k/a Cardinal Distribution, L.P., an Ohio limited partnership (Dublin, Ohio) Cardinal
Health 107, Inc., formerly known as National Pharmpak Services, Inc., an Ohio corporation, Cardinal Health 108, Inc., formerly known as National Specialty Services, Inc., a
Tennessee corporation, and any other subsidiary of Cardinal Health, Inc., an Ohio corporation ("CHI"), as may be designated by CHI. 

QuickLinks

Exhibit 10.32QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.33    
    

April 13,
2006 

Sid
Geller

Cardinal Health

7000 Cardinal Place

Dublin, OH 43017 

	Re:
	AMENDMENT
NO. 2 to the Distribution & Inventory Management Services Agreement 

Dear
Mr. Geller, 

        THIS
AMENDMENT NO. 2, dated as of April 13, 2006 (the "AMENDMENT"), by and between Cardinal Health ("Cardinal") with its principle place of business located at 7000 Cardinal
Place, Dublin, OH 43017 and Prometheus Laboratories Inc. ("Prometheus") with its principle place of business located at 9410 Carroll Park Drive, San Diego, CA 92121, amends the
Distribution & Inventory Management Service Agreement ("DSA") dated as of June 1st, 2004 by and between Cardinal and Prometheus as follows: 

        1.     This
AMENDMENT shall void Cardinal's notice of termination to the DSA dated March 16, 2006. 

        2.     The
first sentence in Article 3, Section 3.1 of the DSA shall be amended to read as follows: "This Agreement shall remain in full
force and effect until December 31, 2007." Except as amended by this AMENDMENT and AMENDMENT NO. 1, all terms and conditions of the DSA shall remain in full force and
effect. 

        Your
signature below will acknowledge your agreement with the above statements and indicate your intent to be legally bound by its content. 

	Sincerely,	 	 
	

/s/  PAUL SKOCZELAS      
 Paul Skoczelas

Senior Manager, Trade Relations

Prometheus Laboratories Inc.	
 	

 

Accepted
and agreed to by: 

	Prometheus Laboratories Inc.	 	Cardinal Health
	

/s/  RON ROCCA      
 Ron Rocca

VP and General Manager GI	
 	

/s/  SID GELLER      
 Sid Geller

Vice President, Supply Chain Purchasing

QuickLinks

Exhibit 10.33QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.34    
    

CERTAIN
MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

AMENDMENT
NO. 3

TO THE DISTRIBUTION & INVENTORY MANAGEMENT

SERVICES AGREEMENT 

This
AMENDMENT NO.3 dated as of December 1, 2007 (the "Amendment"), by and between Cardinal Health Inc, an Ohio Corporation with its principal place of business located at 7000 Cardinal Place,
Dublin, OH 43017 (Cardinal Health"), and Prometheus Laboratories Inc. ("Prometheus"), amends the Distribution & Inventory Management Services Agreement ("DSA"), dated as of
June 1st, 2004 by and between Cardinal Health and Prometheus, as follows (unless otherwise defined herein, all capitalized terms shall have the meaning ascribed to them in the
Agreement): 

	1.
	Article 1, section 1.1 shall be stricken in its entirety and replaced with the following: 

"Aggregate Inventory" means, at any given time, the total sum of Products in units that Cardinal Health has on hand at all of its storage and/or
distribution facilities and that Cardinal Health has on order from Prometheus as determined by the most current 852 data feed. 

	2.
	Article 1, section 1.4 shall be stricken in its entirety and replaced with the following: 

"Average Weekly Movement" means the total quantity of Products in units, by national distribution code ("NDC") number, sold by Cardinal Health to
Customers over the immediately preceding
[***] week period divided by [***], using the most recent [***] weekly 852 reports. Such units will be determined
based on actual "Ship Date" by Cardinal Health to Customers in such [***] week time period. 

	3.
	A new section, 1.13. shall be added to Article 1 as follows: 

"1.13
"Cardinal Direct Returns" shall mean all Product returns that are sent back to Prometheus or its designee by Cardinal only. Such returns shall
specifically exclude any returns that originate from a Customer." 

	4.
	A new section 1.14 shall be added to Article 1 as follows: 

"1.14  "Ship Date" shall mean the date that product is physically shipped from any Cardinal Health facility to a Customer." 

	5.
	A new section 1.15 shall be added to article 1 as follows: 

"1.15
"Price Differential" shall mean the value of the New Price minus the Old Price multiplied by the Price Protected Inventory Units as defined in
Exhibit C. 

***
Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	6.
	The first sentence in Article 3, Section 3.1 shall be stricken in its entirety and replaced with the following: 

"Term
and Termination. This Agreement shall remain in full force and effect until December 31st, 2010 ("Initial Term")".

	7.
	Exhibit C shall be stricken in its entirety and replaced with the following: 

[***].
Prometheus shall pay such fees no later than thirty (30) days after the end of each Calendar Quarter. All such fees will be paid to Cardinal Health in the form of
a credit memo or check as determined by Prometheus. For purposes of this Agreement, a ("Calendar Quarter") shall mean the following calendar periods: January 1—March 31,
April 1—June 30, July 1—September 30, and October 1—December 31. Cardinal Health shall not be entitled to any fees or
payments whatsoever except for those expressly set forth in this Agreement. 

[***].

Example:  

[***]

Agreed
to and accepted by: 

	PROMETHEUS LABORATORIES INC.	 	CARDINAL HEALTH INC.
	

/s/ Joseph M. Limber
	
 	

/s/ Robert J. Sabers

	Name: Joseph M. Limber	 	Name: Robert J. Sabers
	Title: President and Chief Executive Officer	 	Title: VP, Purchasing

***
Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

QuickLinks

Exhibit 10.34QuickLinks
 -- Click here to rapidly navigate through this document
  

 
 

Exhibit 10.35    
    

CERTAIN
MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. 

 
 

SETTLEMENT AGREEMENT AND MUTUAL RELEASE
  AND
  LICENSE AMENDMENT    
    

        This Settlement Agreement and Mutual Release and License Amendment (hereinafter referred to collectively as the "Agreement") is effective as of the
30th day of June, 2006 by and among PROMETHEUS LABORATORIES INC., a California corporation ("Prometheus"), CEDARS-SINAI MEDICAL CENTER, a California nonprofit public benefit corporation
("Cedars-Sinai") and the REGENTS OF THE UNIVERSITY OF CALIFORNIA ("UCLA") acting through its campus at Los Angeles. 

	A.
	WHEREAS
Cedars-Sinai and UCLA have disputed amounts paid by Prometheus to Cedars-Sinai and UCLA for certain past royalty payments in connection with the Exclusive License Agreement, as
amended, entered into among the parties dated August 14, 1996 the "1996 License"), and in connection with the Exclusive License Agreement entered into between UCLA and Prometheus to govern
UCLA's obligations to Prometheus dated December 1, 1999 (the "1999 License")

	B.
	WHEREAS
Prometheus has disputed the amounts claimed as due by Cedars-Sinai and UCLA.

	C.
	WHEREAS
Cedars-Sinai, UCLA and Prometheus wish to modify certain portions of the 1996 License.

	D.
	WHEREAS
UCLA and Prometheus intend that the new terms agreed upon in the settlement will be amended into the 1999 License in order to harmonize the 1996 and 1999 Licenses. 

        NOW,
THEREFORE, for good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the parties enter into this Agreement on the following terms and
conditions: 

AGREEMENT  

	I.
	MUTUAL SETTLEMENTS.

        1.     Prometheus,
Cedars-Sinai and UCLA, without any of them conceding the correctness of the positions of the other, have agreed to settle the above-described dispute existing
among them as of the date hereof in connection with the 1996 License, fully, finally and completely on the following terms: 

        1.1.  In
full and final settlement of any claims of Cedars-Sinai and UCLA related to the payments pursuant to the 1996 License through June 30, 2006, the parties have
agreed to the following: 

	(a)
	As
soon as possible following complete execution of this Agreement, Prometheus shall pay to Cedars-Sinai (on behalf of Cedars-Sinai and UCLA) the sum of [***]
Dollars ($[***]); and

	(b)
	Prometheus
shall calculate Royalties for the quarter ending June 30, 2006 consistent with the calculation of Royalties for the quarter ended March 31, 2006 and will pay
such Royalties to Cedars-Sinai and ULCA by August 15, 2006 as required by the License. 

        1.2.  Cedars-Sinai
and UCLA shall, in consideration of the payments from Prometheus described in paragraph 1.1 above, refrain from pursuing any and all collection
activity, and take all actions necessary to cause any agent or subcontractor to refrain from pursuing any and all collection activity, against Prometheus in connection with any claims resolved by this
Agreement. If 

***
Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

1

 

Prometheus
fails to make the payments described in either paragraphs 1.1(a) or (b) above, Cedars-Sinai and UCLA shall have the right to initiate collection activity for the amount due
and owing under this Agreement and this shall be their sole remedy for breach of Prometheus' obligations under Paragraph 1.1 above. For clarification purposes, except as set forth in
paragraph 1.1 above, Cedars-Sinai and UCLA shall not have the right to pursue collection activities and are forever giving up their rights to any Royalty claims under the License for any period
prior to July 1, 2006. 

        1.3   Prometheus,
Cedars-Sinai and UCLA shall continue to fulfill the obligations set forth in the 1996 License throughout the terms of such 1996 License or in the case of
UCLA and Prometheus the 1999 License where applicable, except as modified by this Agreement. Capitalized terms used in this Agreement but not otherwise defined herein shall have the meanings ascribed
to them in the License. 

        2.     The
parties agree that the initial payment amount described in Section 1.1(a) above is payment in resolution of disputed claims and is being paid to avoid the
expense, inconvenience and uncertainty of litigation. The parties hereto understand and acknowledge that this is a compromise settlement without admission of wrongdoing or liability on the part of
(i) Cedars-Sinai or UCLA; or (ii) Prometheus. 

        3.     The
parties hereby agree that the recipient of the payment described above is responsible for the payment of any and all taxes, if any, and penalties and interest
thereon, which may be assessed on the payment amounts by the state, federal or local government. 

	II.
	AMENDMENT TO LICENSE.

        Effective
as of July 1, 2006, the 1996 License is hereby amended as follows: 

        1.     Section 6(a)
of Schedule J—Definition of "Gross Sales Price" is hereby deleted in its entirety and replaced with the following: 

"(a) "Gross Sales Price" means, for any period, the gross sales price of Products sold which are or include Royalty Bearing Products (whether in the form of cash, property or
otherwise) by Prometheus and its licensees to third parties that are not Affiliates of the selling party (unless such Affiliate is the end user of such Royalty Bearing Product, in which case the
amount billed therefor shall be deemed to be the amount that would be billed to a third party in an arm's-length transaction) during such period, less the following items, as allocable to such Royalty
Bearing Products: (a) discounts including quantity discounts and contractual allowances, (b) credits, rebates or allowances actually granted upon claims, damaged goods, rejections or
returns of Royalty Bearing Products, including recalls, (c) freight, postage, shipping and insurance charges actually allowed or paid for delivery of Royalty Bearing Products, to the extent
billed, (d) taxes, duties or other governmental charges (other than income taxes) levied on, absorbed or otherwise imposed on sales of Royalty Bearing Products, and (e) an estimate for
bad debts determined in accordance with Prometheus' normal accounting procedures consistently applied; all of the above shall be estimated in accordance with United States generally accepted
accounting principles ("GAAP"). In no event shall Royalty Bearing Products used in quality control testing, or Royalty Bearing Products distributed as free marketing samples or charitable
contributions, be considered "sold" for purposes of calculating Gross Sales Price."

        2.    Section 6(c) of Schedule J—Definition of "Royalty Bearing
Product".    Section 6(c) of Schedule J to the 1996 License is hereby deleted in its entirety and replaced with the following: 

"(c) 'Royalty Bearing Product' mean all components, products, features, processes and systems of a Product that (a) are
covered by any of the Patent Rights of Future Patent Rights, or (ii) although not covered by a Patent Right or a Future Patent Right, includes or embodies, Technical  

2

 

 Information or Future Technical Information that is licensed to Prometheus hereunder and is not part of the public domain."

        3.    New Section 6(e) of Schedule J—Definition of "Combination Product".    A new
Section 6(e) of Schedule J to the 1996 License is hereby added to the 1996 License to read in full as follows: 

"(e) 'Combination Product' or 'Combination Products' shall mean any products containing Royalty Bearing Products (as defined in
Section 6(c) hereof) and Other Components (as defined in Section 6(f) hereof)."

        4.    New Section 6(f) of Schedule J—Definition of "Other Components".    A new
Section 6(f) of Schedule J to the 1996 License is hereby added to the 1996 License to read in full as follows: 

"(f) 'Other Component' or 'Other Components' shall mean any and all components, products, features, processes and systems which
are not Royalty Bearing Products."

        5.    Section 1 of Schedule J—Royalties.    The following language is hereby added to the
end of Section 1 of Schedule J to the 1996 License: 

"1. Royalties. Effective July 1, 2006 and notwithstanding anything in the License to the contrary, Prometheus would pay
to Cedars-Sinai and UCLA an additional [***] percent ([***]%) of the Gross Sales Price for the Sale of Royalty Bearing Products or Intellectual Property
(the "Additional Royalty") until there has been a cumulative total of [***] Dollars ($[***]) of such sales subsequent to June 30, 2006. For
clarification purposes, after this aggregate Gross Sales shall have been reached subsequent to June 30, 2006 and the Additional Royalty paid in full by Prometheus, the Additional Royalty shall
cease to be owed by Prometheus and the royalty rate shall return to the level established in the 1996 License.

        Notwithstanding the foregoing, the following shall apply with respect to Combination Products:

        (i)    The Royalty and the Additional Royalty (if applicable) payable on each Combination Product for which standalone Current Procedural Terminology
("CPT") values billed for each part of the Combination Product in a particular country in the Territory, shall be based on the following formula:

[***]  

        [***]

        (ii)   The Royalty payable on each Combination Product for which the Royalty Bearing Products and Other Components contained therein do not have
established, stand-alone [***] in a particular country in the Territory, shall be based on the [***] of each or, failing that, then based on the
[***] for each. Any disagreement between the parties regarding the value for any aspect of a Combination Product shall be determined by the parties through good faith
negotiations.

***
Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

3

 

        6.    Section 4(d) of Schedule J—Late Charges.    Section 4(d) of Schedule J
to the 1996 License is hereby deleted in its entirety. 

        7.    Section 4(b) of Schedule J—Records and Audits.    The following language is hereby
added following the third sentence of Section 4(b) of Schedule J: 

        "Notwithstanding anything in this Agreement to the contrary, such audit right for any period must be (i) exercised within three (3) years of the
date of the payment for the period being audited and (ii) may only be exercised once for any period by either CSMC, UCLA or jointly by CSMC and UCLA."  

        8.    Section 2.3—Certain Future Rights.    The following language is
hereby added to the end of Section 2.3 of the 1996 License: 

        "2.3. Certain Future Rights. .... Notwithstanding the foregoing, Prometheus desires and Cedars-Sinai is willing to
grant to Prometheus additional rights (as specifically set forth in this Section 2.3 and refered to as the "Right of Review") in and to certain aspects of Future Patent Rights identified below
and on the following terms and conditions:

        (a)   In consideration of the grant of the additional rights to certain aspects of Future Patents Rights as identified below as "Cedars-Sinai Future
Rights", as soon as possible following complete execution of this Settlement Agreement and Mutual Release and License Amendment, Prometheus shall pay to Cedars-Sinai (on behalf of Cedars-Sinai only)
the sum of [***] Dollars ($[***]).

        (b)   Cedars-Sinai Future Rights for the purposes of this paragraph shall mean and refer to any patents and/or patent applications (i) claiming
Inventions not previously disclosed to Prometheus pursuant to Section 2.3 of the License which constitute Future Patent Rights or Future Technical Information; (ii) arising from work
conducted by Targan or under the direction of Targan as the sole principal investigator for Cedars-Sinai; (iii) in addition to any patents and/or patent applications (including provisional
patent applications) in any other country corresponding to any of the foregoing, and all divisions, continuations, continuations-in-part, reissues, reexaminations,
supplementary protection certificates and extensions thereof, whether domestic or foreign, and any patents that issue thereon; and (iv) on which no prior right or obligation to a third party
exists. For the sake of clarity, it is understood and agreed by the parties that no additional rights are intended, nor shall it be deemed, to be granted to Future Patent Rights of UCLA and the
definition of Cedars-Sinai Future Rights explicity excludes any such rights.

        (c)   The Right of Review granted to Prometheus by Cedars-Sinai (i) applies to any Cedars-Sinai Future Rights which have gone beyond the
[***] day period established in Section 2.3; and (ii) requires Cedars-Sinai to contact Prometheus prior to entering into substantive discussions with a
third party for a possible license to any Cedars-Sinai Future Rights. Cedars-Sinai and Prometheus shall have a period of [***] days in which to negotiate the terms of a
license for the Cedars-Sinai Future Rights. If Prometheus declines or fails to pursue, or if the parties fail to conclude negotiations for a license to, such Cedars-Sinai Future Rights during the
[***] day period, Cedars-Sinai shall have the right to commence discussions with the third party concerning that particular Cedars-Sinai Future Right, provided, however,
that any such license must be on terms that are no less favorable than those of the terms last offered by Prometheus, if any, for such Cedars-Sinai Future Rights."

	III.
	PROMETHEUS RELEASES.

        1.     Prometheus
hereby expressly releases and waives, and absolutely and forever discharges Cedars-Sinai, UCLA and each of their respective affiliates, related entities,
officers, directors, parent corporations, subsidiaries, shareholders, agents, representatives, employees, former employees, 

***
Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

4

 

attorneys,
trustees, licensing agencies, insurers, predecessors, successors, and assigns, individually and collectively, from any and all charges, complaints, arbitrations, claims, liabilities,
demands, debts, accounts, obligations, actions, attorney fees and causes of action (collectively referred to as "Legal Actions"), past, present, or future, known or unknown, suspected or unsuspected,
at law or in equity or in arbitration, of any kind or nature whatsoever, which Prometheus has or claims to have against any or all of them, now or hereafter, relating to any payments pursuant to the
1996 License accrued, paid or due through June 30, 2006 other than as specified in this Agreement. 

        2.     As
part of the above release, and not by way of limitation, Prometheus expressly, absolutely, and forever releases and waives all of its rights under Section 1542
of the Civil Code of the State of California pertaining to such payments pursuant to the 1996 License. Said Section states: 

"A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS/HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM/HER, MUST HAVE MATERIALLY
AFFECTED THE SETTLEMENT WITH THE DEBTOR." 

        3.     Prometheus
represents and warrants that it is not a party to or aware of any pending or potential lawsuit, action, claim, arbitration or charge on its behalf against
Cedars-Sinai and/or UCLA related to the 1996 License. 

        4.     Prometheus
agrees that this Agreement and all of its terms shall be binding upon its assignees, employees, agents, affiliates, parent corporations, subsidiaries or other
related entities, and the assignees of such entities. 

	IV.
	CEDARS-SINAI RELEASES.

        1.     Cedars-Sinai
hereby expressly releases and waives, and absolutely and forever discharges Prometheus, UCLA and their respective affiliates, related entities, officers,
directors, parent corporations, subsidiaries, shareholders, agents, representatives, employees, former employees, attorneys, trustees, licensing agencies, insurers, predecessors, successors, and
assigns, individually and collectively, from any and all Legal Actions, past, present, or future, known or unknown, suspected or unsuspected, at law or in equity or in arbitration, of any kind or
nature whatsoever, which Cedars-Sinai has or claims to have against any or all of them, now or hereafter, relating to any payments pursuant to the 1996 License accrued, paid or due through
June 30, 2006 other than as specified in this Agreement. 

        2.     As
part of the above release, and not by way of limitation, Cedars-Sinai expressly, absolutely, and forever releases and waives all of its rights under
Section 1542 of the Civil Code of the State of California pertaining to any such payments pursuant to the 1996 License. Said Section states: 

"A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS/HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM/HER, MUST HAVE MATERIALLY
AFFECTED THE SETTLEMENT WITH THE DEBTOR." 

        3.     Cedars-Sinai
represents and warrants that it is not a party to or aware of any pending or potential lawsuit, action, claim, arbitration or charge on its behalf against
Prometheus and/or UCLA related to the 1996 License. 

        4.     Cedars-Sinai
agrees that this Agreement and all of its terms shall be binding upon its assignees, employees, agents, affiliates, parent corporations, subsidiaries or
other related entities, and the assignees of such entities. 

	V.
	UCLA RELEASES.

        1.     UCLA
hereby expressly releases and waives, and absolutely and forever discharges Prometheus, Cedars-Sinai and each of their respective affiliates, related entities,
officers, directors, 

5

 

parent
corporations, subsidiaries, shareholders, agents, representatives, employees, former employees, attorneys, trustees, licensing agencies, insurers, predecessors, successors, and assigns,
individually and collectively, from any and all Legal Actions, past, present, or future, known or unknown, suspected or unsuspected, at law or in equity or in arbitration, of any kind or nature
whatsoever, which UCLA has or claims to have against any or all of them, now or hereafter, related to any payments pursuant to the 1996 License accrued, paid or due through June 30, 2006 other
than as specified in this Agreement. 

        2.     As
part of the above release, and not by way of limitation, UCLA expressly, absolutely, and forever releases and waives all of its rights under Section 1542 of the
Civil Code of the State of California pertaining to any such payments pursuant to the License. Said Section states: 

"A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS/HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM/HER, MUST HAVE MATERIALLY
AFFECTED THE SETTLEMENT WITH THE DEBTOR." 

        3.     UCLA
represents and warrants that it is not a party to or aware of any pending or potential lawsuit, action, claim, arbitration or charge on its behalf against Prometheus
and/or Cedars-Sinai related to the 1996 License. 

        4.     UCLA
agrees that this Agreement and all of its terms shall be binding upon its assignees, employees, agents, affiliates, parent corporations, subsidiaries or other
related entities, and the assignees of such entities. 

	VI.
	NON-DISCLOSURE.

        Notwithstanding
anything herein to the contrary, except as required by law or regulation, each of the parties hereto and its attorneys of record, hereby agree that they will not
publicize or disclose in any manner whatsoever, this Agreement, or the contents, terms, or any part hereof, whether in writing or orally, directly or indirectly, to any person or entity whomsoever,
including, without limitation, any members of the press or other media. The parties understand and agree that this paragraph is a material provision of this Agreement entitling each nondisclosing
party to any and all remedies available under law, including recision of this Agreement. 

	VII.
	[***]

        In
the event that any action, suit or other proceeding is instituted to remedy, prevent, or obtain relief from a breach of this Agreement, or arising out of a breach of this Agreement,
[***] 

	VIII.
	ENTIRE AGREEMENT.

        This
Agreement constitutes and contains the entire agreement and understanding concerning the subject matter between the parties hereto, and supersedes and replaces all prior
negotiations, all proposed agreements, and all agreements, whether written or oral, express or implied, concerning the subject matter hereof. Each party acknowledges that it has not signed this
Agreement in reliance on any promise, representation, or warranty whatsoever, express or implied, written or oral, not contained herein concerning the subject matter hereof. The parties hereto further
agree that any oral representations or modifications of this Agreement shall be of no force or effect unless agreed to in writing by each party hereto. 

	IX.
	APPLICABLE LAW.

        This
Agreement is executed and delivered within the State of California and shall in all respects be interpreted, enforced, and governed by and under the laws of the State of California. 

	X.
	ACKNOWLEDGMENT OF REPRESENTATION.

        Each
party acknowledges that it has been represented by competent counsel in connection with this matter and that each of them have executed this Agreement with the consent of and on the
advice of such counsel. Each party acknowledges that it has read this Agreement and fully understands and consents to all its terms and conditions without any reservations whatsoever. All parties
acknowledge that they have had adequate opportunity to make whatever investigation or inquiry they deem necessary and advisable in connection with the subject matters of this Agreement prior to the
execution thereof. 

	XI.
	COUNTERPARTS.

        This
Agreement may be executed in any number of counterparts, and when each party has signed and delivered at least one such counterpart to the other parties hereto, each counterpart
shall be deemed an original and taken together shall constitute one and the same Agreement, which shall be binding and effective as to all the parties hereto. 

***
Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

6

 

        IN
WITNESS WHEREOF, the parties hereto have set their hands as of the date first set forth above. 

        PLEASE
READ CAREFULLY. THIS AGREEMENT INCLUDES A RELEASE OF CERTAIN KNOWN AND UNKNOWN CLAIMS. 

	 	 	PROMETHEUS LABORATORIES INC.
	

 	
 	

By:	

/s/  JOSEPH M. LIMBER      
 Name: Joseph M. Limber

Title: President and Chief Executive Officer
	

 	
 	

CEDARS-SINAI MEDICAL CENTER
	

 	
 	

By:	

/s/  EDWARD M. PRUNCHUNAS      
 Edward M. Prunchunas

Senior Vice President for Finance
	

 	
 	

By:	

/s/  RICHARD S. KATZMAN      
 Richard S. Katzman

Vice President for Academic Affairs
	

 	
 	

REGENTS OF THE UNIVERSITY OF CALIFORNIA

acting by and through its campus at Los Angeles

	

 	
 	

By:	

/s/  EMILY W. LOUGHRAN      

	 	 	Name:	Emily W. Loughran

	 	 	Title:	Director, Licensing

7

QuickLinks

Exhibit 10.35

SETTLEMENT AGREEMENT AND MUTUAL RELEASE AND LICENSE AMENDMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00136-of-00352.parquet"}]]